The efficacy and safety of selumetinib as secondary therapy for late-stage and metastatic non-small cell lung cancer: results from a systematic review and meta-analysis.

Ann Transl Med · 2022 · PMC9201184 · PMID 35722363

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although selumetinib showed superior efficacy over the reported chemotherapies and immunotherapies, the difference did not reach statistical significance even when compared to placebo.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.